RCM Stock Overview
Provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for RCM from our risk checks.
R1 RCM Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.86 |
| 52 Week High | US$18.71 |
| 52 Week Low | US$8.87 |
| Beta | 0.78 |
| 1 Month Change | 3.13% |
| 3 Month Change | -7.95% |
| 1 Year Change | -23.27% |
| 3 Year Change | -40.74% |
| 5 Year Change | 4.89% |
| Change since IPO | -5.09% |
Recent News & Updates
Recent updates
Voss Capital - R1 RCM Inc.: Bull Case Achievable Despite Negative Sentiment
Mar 03Calculating The Fair Value Of R1 RCM Inc. (NASDAQ:RCM)
Oct 03
Returns At R1 RCM (NASDAQ:RCM) Are On The Way Up
Sep 03Is Now An Opportune Moment To Examine R1 RCM Inc. (NASDAQ:RCM)?
Jul 18Why We're Not Concerned About R1 RCM Inc.'s (NASDAQ:RCM) Share Price
Jul 03R1 RCM Inc. (NASDAQ:RCM) Shares Could Be 40% Below Their Intrinsic Value Estimate
Jun 05R1 RCM Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 06R1 RCM (NASDAQ:RCM) Might Have The Makings Of A Multi-Bagger
Mar 17Is R1 RCM Inc. (NASDAQ:RCM) Trading At A 42% Discount?
Jan 06R1 RCM slides 7% on secondary stock offering by selling shareholder
Sep 08R1 RCM's (NASDAQ:RCM) Promising Earnings May Rest On Soft Foundations
Aug 11R1 RCM GAAP EPS of -$0.07 misses by $0.11, revenue of $391.9M in-line
Aug 03R1 RCM: Long-Term Growth Story Intact Following Cloudmed Acquisition
Jul 19News Flash: Analysts Just Made A Meaningful Upgrade To Their R1 RCM Inc. (NASDAQ:RCM) Forecasts
Jun 30R1 RCM draws bullish views at Barclays on Cloudmed acquisition
Jun 29Shareholder Returns
| RCM | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 3.0% | 0.3% | -0.6% |
| 1Y | -23.3% | 1.3% | 22.5% |
Return vs Industry: RCM underperformed the US Healthcare industry which returned 1.3% over the past year.
Return vs Market: RCM underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| RCM volatility | |
|---|---|
| RCM Average Weekly Movement | 3.4% |
| Healthcare Industry Average Movement | 6.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RCM has not had significant price volatility in the past 3 months.
Volatility Over Time: RCM's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 29,650 | Lee Rivas | www.r1rcm.com |
R1 RCM Inc. provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers. The company also offers modular solutions, including functional partnership, an outsourcing solutions for improvements across targeted revenue cycle areas for hospital and physician group customers; revenue recovery, to fast-track payer and patient cash collections; revenue optimization, a solution to uncover missed or underreported revenue; clinical integrity, used to improve documentation and coding accuracy to maximize earned revenue for the services provided; and regulatory navigation, a compliance-first solutions for government reimbursement accuracy, pharmacy savings, and compliance.
R1 RCM Inc. Fundamentals Summary
| RCM fundamental statistics | |
|---|---|
| Market cap | US$5.42b |
| Earnings (TTM) | -US$33.40m |
| Revenue (TTM) | US$2.31b |
2.3x
P/S Ratio-162.2x
P/E RatioIs RCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RCM income statement (TTM) | |
|---|---|
| Revenue | US$2.31b |
| Cost of Revenue | US$1.83b |
| Gross Profit | US$479.90m |
| Other Expenses | US$513.30m |
| Earnings | -US$33.40m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.079 |
| Gross Margin | 20.75% |
| Net Profit Margin | -1.44% |
| Debt/Equity Ratio | 80.8% |
How did RCM perform over the long term?
See historical performance and comparison